{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:31:02Z","timestamp":1790188262292,"version":"4.1.0"},"reference-count":300,"publisher":"American Association for Cancer Research (AACR)","issue":"2","funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA068485"],"award-info":[{"award-number":["P30 CA068485"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":["Cancer Discov"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1158\/2159-8290.cd-21-1368","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T15:15:18Z","timestamp":1639149318000},"page":"303-330","update-policy":"https:\/\/doi.org\/10.1158\/aacr-crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer"],"prefix":"10.1158","volume":"12","author":[{"given":"Arielle","family":"Elkrief","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-1827","authenticated-orcid":false,"given":"Julie T.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6917-5568","authenticated-orcid":false,"given":"Chinmay","family":"Jani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1901-5558","authenticated-orcid":false,"given":"Kyle T.","family":"Enriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8884-3085","authenticated-orcid":false,"given":"Mansi R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5604-4166","authenticated-orcid":false,"given":"Hira Ghazal","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Beeghly-Fadiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8604-4757","authenticated-orcid":false,"given":"Sachin R.","family":"Jhawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4565-4556","authenticated-orcid":false,"given":"Donna R.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.","family":"Reuben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2612-9040","authenticated-orcid":false,"given":"Stacey L.","family":"Tinianov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald Cuong","family":"Vinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7775-9600","authenticated-orcid":false,"given":"Sanjay","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2851-7242","authenticated-orcid":false,"given":"Jeremy L.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"2022020901350736000_12.2.303.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6"},{"key":"2022020901350736000_12.2.303.2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0422"},{"key":"2022020901350736000_12.2.303.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31187-9"},{"key":"2022020901350736000_12.2.303.4","doi-asserted-by":"crossref","first-page":"1073274821997425","DOI":"10.1177\/1073274821997425","article-title":"The effects of COVID-19 on cancer care provision: a systematic review","volume":"28","author":"Alom","year":"2021","journal-title":"Cancer Control"},{"key":"2022020901350736000_12.2.303.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20568-4"},{"key":"2022020901350736000_12.2.303.6","doi-asserted-by":"crossref","first-page":"682154","DOI":"10.3389\/fpsyg.2021.682154","article-title":"Psychological distress among cancer patients during COVID-19 pandemic in the world: a systematic review","volume":"12","author":"Momenimovahed","year":"2021","journal-title":"Front Psychol"},{"key":"2022020901350736000_12.2.303.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30388-0"},{"key":"2022020901350736000_12.2.303.8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V'kovski","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"2022020901350736000_12.2.303.9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","article-title":"Age-specific mortality and immunity patterns of SARS-CoV-2","volume":"590","author":"O'Driscoll","year":"2021","journal-title":"Nature"},{"key":"2022020901350736000_12.2.303.10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fpubh.2020.00152","article-title":"Gender differences in patients with COVID-19: focus on severity and mortality","volume":"8","author":"Jin","year":"2020","journal-title":"Front Public Health"},{"key":"2022020901350736000_12.2.303.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001316"},{"key":"2022020901350736000_12.2.303.12","doi-asserted-by":"crossref","first-page":"101075","DOI":"10.1016\/j.eclinm.2021.101075","article-title":"Racial and ethnic disparity in clinical outcomes among patients with confirmed COVID-19 infection in a large US electronic health record database","volume":"39","author":"Buikema","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2022020901350736000_12.2.303.13","doi-asserted-by":"crossref","first-page":"ofab388","DOI":"10.1093\/ofid\/ofab388","article-title":"Demographic and clinical factors associated with death among persons <21 years old with multisystem inflammatory syndrome in children\u2014United States, February 2020\u2013March 2021","volume":"8","author":"Bowen","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022020901350736000_12.2.303.14","doi-asserted-by":"crossref","first-page":"e13128","DOI":"10.1111\/obr.13128","article-title":"Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships","volume":"21","author":"Popkin","year":"2020","journal-title":"Obes Rev"},{"key":"2022020901350736000_12.2.303.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.08.017"},{"key":"2022020901350736000_12.2.303.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.024"},{"key":"2022020901350736000_12.2.303.17","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6915e3"},{"key":"2022020901350736000_12.2.303.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.08.009"},{"key":"2022020901350736000_12.2.303.19","doi-asserted-by":"crossref","first-page":"646333","DOI":"10.3389\/fimmu.2021.646333","article-title":"Cellular immune response to COVID-19 and potential immune modulators","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"2022020901350736000_12.2.303.20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ijid.2020.07.003","article-title":"Dynamic changes in peripheral blood lymphocyte subsets in adult patients with COVID-19","volume":"98","author":"Deng","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2022020901350736000_12.2.303.21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ccell.2020.09.018","article-title":"COVID-19 and cancer: current challenges and perspectives","volume":"38","author":"Bakouny","year":"2020","journal-title":"Cancer Cell"},{"key":"2022020901350736000_12.2.303.22","doi-asserted-by":"publisher","DOI":"10.1038\/S41579-021-00573-0"},{"key":"2022020901350736000_12.2.303.23","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","volume":"27","author":"Shi","year":"2020","journal-title":"Cell Death Differ"},{"key":"2022020901350736000_12.2.303.24","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s10875-021-01068-6","article-title":"Harnessing type I IFN immunity against SARS-CoV-2 with early administration of IFN-\u03b2","volume":"41","author":"Vinh","year":"2021","journal-title":"J Clin Immunol"},{"key":"2022020901350736000_12.2.303.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0485-4"},{"key":"2022020901350736000_12.2.303.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"2022020901350736000_12.2.303.27","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41586-020-3014-1","article-title":"Progenitor identification and SARS-CoV-2 infection in human distal lung organoids","volume":"588","author":"Salahudeen","year":"2020","journal-title":"Nature"},{"key":"2022020901350736000_12.2.303.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.028"},{"key":"2022020901350736000_12.2.303.29","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.chom.2021.05.004","article-title":"Innate immune and inflammatory responses to SARS-CoV-2: implications for COVID-19","volume":"29","author":"Lowery","year":"2021","journal-title":"Cell Host Microbe"},{"key":"2022020901350736000_12.2.303.30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coviro.2021.06.007","article-title":"Animal models of SARS-CoV-2 transmission","volume":"50","author":"de Vries","year":"2021","journal-title":"Curr Opin Virol"},{"key":"2022020901350736000_12.2.303.31","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4570"},{"key":"2022020901350736000_12.2.303.32","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl4348"},{"key":"2022020901350736000_12.2.303.33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.13719"},{"key":"2022020901350736000_12.2.303.34","doi-asserted-by":"crossref","first-page":"719115","DOI":"10.3389\/fimmu.2021.719115","article-title":"Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19","volume":"12","author":"Solanich","year":"2021","journal-title":"Front Immunol"},{"key":"2022020901350736000_12.2.303.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.06.005"},{"key":"2022020901350736000_12.2.303.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03065-y"},{"key":"2022020901350736000_12.2.303.37","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4585"},{"key":"2022020901350736000_12.2.303.38","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s10875-021-01036-0","article-title":"Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain","volume":"41","author":"Troya","year":"2021","journal-title":"J Clin Immunol"},{"key":"2022020901350736000_12.2.303.39","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01060-0"},{"key":"2022020901350736000_12.2.303.40","doi-asserted-by":"crossref","first-page":"e1327","DOI":"10.1002\/cti2.1327","article-title":"Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients","volume":"10","author":"Goncalves","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"2022020901350736000_12.2.303.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03631-y"},{"key":"2022020901350736000_12.2.303.42","doi-asserted-by":"crossref","first-page":"eabh2624","DOI":"10.1126\/scitranslmed.abh2624","article-title":"Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19","volume":"13","author":"van der Wijst","year":"2021","journal-title":"Sci Transl Med"},{"key":"2022020901350736000_12.2.303.43","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl4340"},{"key":"2022020901350736000_12.2.303.44","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2011.109"},{"key":"2022020901350736000_12.2.303.45","doi-asserted-by":"crossref","first-page":"e140329","DOI":"10.1172\/jci.insight.140329","article-title":"Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections","volume":"5","author":"Remy","year":"2020","journal-title":"JCI Insight"},{"key":"2022020901350736000_12.2.303.46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2648.1988.tb01397.x","article-title":"Health promotion in the family: current findings and directives for nursing research","volume":"13","author":"Duffy","year":"1988","journal-title":"J Adv Nurs"},{"key":"2022020901350736000_12.2.303.47","doi-asserted-by":"publisher","DOI":"10.1111\/all.14364"},{"key":"2022020901350736000_12.2.303.48","doi-asserted-by":"publisher","DOI":"10.1038\/nri1732"},{"key":"2022020901350736000_12.2.303.49","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","article-title":"A dynamic COVID-19 immune signature includes associations with poor prognosis","volume":"26","author":"Laing","year":"2020","journal-title":"Nat Med"},{"key":"2022020901350736000_12.2.303.50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01441"},{"key":"2022020901350736000_12.2.303.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"2022020901350736000_12.2.303.52","doi-asserted-by":"crossref","unstructured":"Tembhare PR Sriram H Chatterjee G Khanka T Gokarn A Mirgh S Comprehensive immune cell profiling depicts an early immune response associated with severe coronavirus disease 2019 in cancer patients. Immunol Cell Biol 2021 Sep 28 [Epub ahead of print].","DOI":"10.1111\/imcb.12504"},{"key":"2022020901350736000_12.2.303.53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lfs.2014.02.011","article-title":"Anxiolytic-like effect of danshensu [(3-(3,4-dihydroxyphenyl)-lactic acid)] in mice","volume":"101","author":"Kwon","year":"2014","journal-title":"Life Sci"},{"key":"2022020901350736000_12.2.303.54","doi-asserted-by":"crossref","first-page":"e1619","DOI":"10.1002\/onco.13828","article-title":"Humoral immune response of SARS-CoV-2-infected patients with cancer: influencing factors and mechanisms","volume":"26","author":"Esperan\u00e7a-Martins","year":"2021","journal-title":"Oncologist"},{"key":"2022020901350736000_12.2.303.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.03.033"},{"key":"2022020901350736000_12.2.303.56","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jmv.26232","article-title":"The cytokine storm and COVID-19","volume":"93","author":"Hu","year":"2021","journal-title":"J Med Virol"},{"key":"2022020901350736000_12.2.303.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"2022020901350736000_12.2.303.58","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s43018-021-00275-9","article-title":"Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nat Cancer"},{"key":"2022020901350736000_12.2.303.59","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"key":"2022020901350736000_12.2.303.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.01.001"},{"key":"2022020901350736000_12.2.303.61","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1038\/s41418-021-00817-9","article-title":"Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis","volume":"28","author":"Goubet","year":"2021","journal-title":"Cell Death Differ"},{"key":"2022020901350736000_12.2.303.62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031670"},{"key":"2022020901350736000_12.2.303.63","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaoncol.2020.0980","article-title":"SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"key":"2022020901350736000_12.2.303.64","doi-asserted-by":"crossref","first-page":"102068","DOI":"10.1016\/j.ctrv.2020.102068","article-title":"SARS-CoV-2 and cancer: are they really partners in crime?","volume":"89","author":"van Dam","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2022020901350736000_12.2.303.65","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s12967-020-02483-w","article-title":"Cancer patients and coronavirus disease 2019: evidence in context","volume":"18","author":"Barba","year":"2020","journal-title":"J Transl Med"},{"key":"2022020901350736000_12.2.303.66","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06062-x"},{"key":"2022020901350736000_12.2.303.67","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0773"},{"key":"2022020901350736000_12.2.303.68","doi-asserted-by":"crossref","first-page":"e002277corr1","DOI":"10.1136\/jitc-2020-002277corr1","article-title":"Correction: Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score","volume":"9","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2022020901350736000_12.2.303.69","doi-asserted-by":"crossref","first-page":"100123","DOI":"10.1016\/j.esmoop.2021.100123","article-title":"The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer","volume":"6","author":"Dettorre","year":"2021","journal-title":"ESMO Open"},{"key":"2022020901350736000_12.2.303.70","doi-asserted-by":"crossref","unstructured":"Hempel D Milani V Kleespies A Hempel L Ebner F Zehn D SARS-CoV-2 infections in outpatients with cancer: most infected patients are asymptomatic carriers without impact on chemotherapy. Ann Oncol 2020;31 (Suppl 4):S995. Abstract nr 1680P.","DOI":"10.1016\/j.annonc.2020.08.1744"},{"key":"2022020901350736000_12.2.303.71","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/j.clon.2020.11.006","article-title":"Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis","volume":"33","author":"Zarifkar","year":"2021","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"2022020901350736000_12.2.303.72","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jamaoncol.2020.6178","article-title":"Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"2022020901350736000_12.2.303.73","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.03.035","article-title":"Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study","volume":"150","author":"Pinato","year":"2021","journal-title":"Eur J Cancer"},{"key":"2022020901350736000_12.2.303.74","article-title":"Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK","volume":"32 (Suppl 5):S1129\u201363. Abstract","author":"Palmieri","year":"2021","journal-title":"Ann Oncol"},{"key":"2022020901350736000_12.2.303.75","doi-asserted-by":"crossref","unstructured":"Pinato DJ Patel M Lambertini M Colomba E Pommeret F Van Hemelrijick M Time-dependent improvement in the clinical outcomes from COVID-19 in cancer patients: an updated analysis of the OnCovid registry. Ann Oncol 2021;32 (Suppl 5):S1129\u201363. Abstract nr 1565MO.","DOI":"10.1016\/j.annonc.2021.08.1558"},{"key":"2022020901350736000_12.2.303.76","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S1470-2045(21)00573-8","article-title":"Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study","volume":"22","author":"Pinato","year":"2021","journal-title":"Lancet Oncol"},{"key":"2022020901350736000_12.2.303.77","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2020.09.027","article-title":"Dutch Oncology COVID-19 Consortium: outcome of COVID-19 in patients with cancer in a nationwide cohort study","volume":"141","author":"de Joode","year":"2020","journal-title":"Eur J Cancer"},{"key":"2022020901350736000_12.2.303.78","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2020.09.035","article-title":"Risk factors for coronavirus disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19)","volume":"141","author":"Li\u00e8vre","year":"2020","journal-title":"Eur J Cancer"},{"key":"2022020901350736000_12.2.303.79","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30314-4"},{"key":"2022020901350736000_12.2.303.80","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1200\/GO.21.00087","article-title":"Outcomes and prognostic factors in a large cohort of hospitalized cancer patients with COVID-19","volume":"7","author":"Marta","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"2022020901350736000_12.2.303.81","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"key":"2022020901350736000_12.2.303.82","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa159"},{"key":"2022020901350736000_12.2.303.83","doi-asserted-by":"crossref","unstructured":"Shiels MS Haque AT Haozous EA Albert PS Almeida JS Garc\u00eda-Closas M Racial and ethnic disparities in excess deaths during the COVID-19 pandemic, March to December 2020. Ann Intern Med 2021 ;174:1693\u20139.","DOI":"10.7326\/M21-2134"},{"key":"2022020901350736000_12.2.303.84","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0941"},{"key":"2022020901350736000_12.2.303.85","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ccell.2020.10.023","article-title":"Cancer care disparities during the COVID-19 pandemic: COVID-19 and Cancer Outcomes Study","volume":"38","author":"Schmidt","year":"2020","journal-title":"Cancer Cell"},{"key":"2022020901350736000_12.2.303.86","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7197"},{"key":"2022020901350736000_12.2.303.87","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/1090198120929677","article-title":"Social vulnerability and racial inequality in COVID-19 deaths in Chicago","volume":"47","author":"Kim","year":"2020","journal-title":"Health Educ Behav"},{"key":"2022020901350736000_12.2.303.88","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.8598"},{"key":"2022020901350736000_12.2.303.89","doi-asserted-by":"publisher","DOI":"10.1037\/dev0000511"},{"key":"2022020901350736000_12.2.303.90","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01283-z"},{"key":"2022020901350736000_12.2.303.91","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/01410768211032850","article-title":"Symptoms, complications and management of long COVID: a review","volume":"114","author":"Aiyegbusi","year":"2021","journal-title":"J R Soc Med"},{"key":"2022020901350736000_12.2.303.92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254347"},{"key":"2022020901350736000_12.2.303.93","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.dsx.2021.04.007","article-title":"Long COVID: an overview","volume":"15","author":"Raveendran","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"2022020901350736000_12.2.303.94","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2024358118"},{"key":"2022020901350736000_12.2.303.95","unstructured":"Matta J Wiernik E Robineau O Carrat F Touvier M Severi G Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern Med 2021 Nov 8 [Epub ahead of print]."},{"key":"2022020901350736000_12.2.303.96","doi-asserted-by":"crossref","first-page":"S1129","DOI":"10.1016\/j.annonc.2021.08.1553","article-title":"Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of cancer patients who recovered from SARS-CoV-2 infection","volume":"32","author":"Cortellini","year":"2021","journal-title":"Ann Oncol"},{"key":"2022020901350736000_12.2.303.97","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2217\/imt-2021-0007","article-title":"Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis","volume":"13","author":"Qian","year":"2021","journal-title":"Immunotherapy"},{"key":"2022020901350736000_12.2.303.98","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S2665-9913(20)30120-X","article-title":"The immunology of COVID-19: is immune modulation an option for treatment?","volume":"2","author":"Zhong","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2022020901350736000_12.2.303.99","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat Med"},{"key":"2022020901350736000_12.2.303.100","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30309-0"},{"key":"2022020901350736000_12.2.303.101","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0596"},{"key":"2022020901350736000_12.2.303.102","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet North Am Ed"},{"key":"2022020901350736000_12.2.303.103","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001931"},{"key":"2022020901350736000_12.2.303.104","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.1002\/onco.13768","article-title":"Risk of COVID-19 in patients with cancer receiving immune checkpoint inhibitors","volume":"26","author":"Klebanov","year":"2021","journal-title":"Oncologist"},{"key":"2022020901350736000_12.2.303.105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01074"},{"key":"2022020901350736000_12.2.303.106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.09.028"},{"key":"2022020901350736000_12.2.303.107","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA"},{"key":"2022020901350736000_12.2.303.108","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000234355","article-title":"T cell activation surface markers and autologous mixed lymphocyte reaction do not differ in true and pseudo food allergy","volume":"83","author":"Dirienzo","year":"1987","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"2022020901350736000_12.2.303.109","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0717"},{"key":"2022020901350736000_12.2.303.110","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000984"},{"key":"2022020901350736000_12.2.303.111","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann Oncol"},{"key":"2022020901350736000_12.2.303.112","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30442-3"},{"key":"2022020901350736000_12.2.303.113","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3731"},{"key":"2022020901350736000_12.2.303.114","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.20.01307","article-title":"Chemotherapy and COVID-19 outcomes in patients with cancer","volume":"38","author":"Jee","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022020901350736000_12.2.303.115","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"2022020901350736000_12.2.303.116","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol"},{"key":"2022020901350736000_12.2.303.117","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","article-title":"Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"2022020901350736000_12.2.303.118","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(20)31182-X","article-title":"Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study","volume":"396","author":"COVIDS Collaborative","year":"2020","journal-title":"Lancet"},{"key":"2022020901350736000_12.2.303.119","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.radonc.2021.06.002","article-title":"Association of prior radiation dose to the cardiopulmonary system with COVID-19 outcomes in patients with cancer","volume":"161","author":"LaPlant","year":"2021","journal-title":"Radiother Oncol"},{"key":"2022020901350736000_12.2.303.120","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.annonc.2020.04.479","article-title":"Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)","volume":"31","author":"Montopoli","year":"2020","journal-title":"Ann Oncol"},{"key":"2022020901350736000_12.2.303.121","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.023"},{"key":"2022020901350736000_12.2.303.122","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JU.0000000000001338","article-title":"Androgen deprivation therapy in men with prostate cancer does not affect risk of infection with SARS-CoV-2","volume":"205","author":"Klein","year":"2021","journal-title":"J Urol"},{"key":"2022020901350736000_12.2.303.123","unstructured":"Karimi A Nowroozi A Alilou S Amini E . Effects of androgen deprivation therapy on COVID-19 in patients with prostate cancer: a systematic review and meta-analysis. Urol J 2021 Jul 24 [Epub ahead of print]."},{"key":"2022020901350736000_12.2.303.124","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.annonc.2020.06.015","article-title":"Androgen deprivation and SARS-CoV-2 in men with prostate cancer","volume":"31","author":"Koskinen","year":"2020","journal-title":"Ann Oncol"},{"key":"2022020901350736000_12.2.303.125","doi-asserted-by":"crossref","first-page":"e2134330","DOI":"10.1001\/jamanetworkopen.2021.34330","article-title":"Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19","volume":"4","author":"Schmidt","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2022020901350736000_12.2.303.126","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1038\/s41598-021-86859-y","article-title":"Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial","volume":"11","author":"Darazam","year":"2021","journal-title":"Sci Rep"},{"key":"2022020901350736000_12.2.303.127","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01061"},{"key":"2022020901350736000_12.2.303.128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.019"},{"key":"2022020901350736000_12.2.303.129","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1021\/acs.jcim.1c00524","article-title":"Drug repurposing to identify nilotinib as a potential SARS-CoV-2 main protease inhibitor: insights from a computational and in vitro study","volume":"61","author":"Banerjee","year":"2021","journal-title":"J Chem Inf Model"},{"key":"2022020901350736000_12.2.303.130","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1002\/cncr.33130","article-title":"Low-dose whole-lung radiation for COVID-19 pneumonia: planned day 7 interim analysis of a registered clinical trial","volume":"126","author":"Hess","year":"2020","journal-title":"Cancer"},{"key":"2022020901350736000_12.2.303.131","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ccell.2021.04.006","article-title":"Care without a compass: including patients with cancer in COVID-19 studies","volume":"39","author":"Friese","year":"2021","journal-title":"Cancer Cell"},{"key":"2022020901350736000_12.2.303.132","doi-asserted-by":"crossref","first-page":"112107","DOI":"10.1016\/j.biopha.2021.112107","article-title":"Recent advances in management of COVID-19: a review","volume":"143","author":"Mouffak","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2022020901350736000_12.2.303.133","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1182\/blood.2020008248","article-title":"Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition","volume":"136","author":"Yu","year":"2020","journal-title":"Blood"},{"key":"2022020901350736000_12.2.303.134","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0343-0"},{"key":"2022020901350736000_12.2.303.135","doi-asserted-by":"crossref","unstructured":"Ma L Sahu SK Cano M Kuppuswamy V Bajwa J McPhatter J Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci Immunol 2021;6:eabh2259.","DOI":"10.1126\/sciimmunol.abh2259"},{"key":"2022020901350736000_12.2.303.136","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2022020901350736000_12.2.303.137","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2021.39.15_suppl.3137","article-title":"Outcomes of active cancer patients with COVID-19 infection treated with COVID-19 neutralizing monoclonal antibodies","volume":"39","author":"Shaya","year":"2021","journal-title":"J Clin Oncol"},{"key":"2022020901350736000_12.2.303.138","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19","volume":"7","author":"Thompson","year":"2021","journal-title":"JAMA Oncol"},{"key":"2022020901350736000_12.2.303.139","doi-asserted-by":"crossref","first-page":"e1397","DOI":"10.1093\/cid\/ciab397","article-title":"Improving the outcomes of immunocompromised patients with coronavirus disease 2019","volume":"73","author":"Haidar","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022020901350736000_12.2.303.140","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30304-4"},{"key":"2022020901350736000_12.2.303.141","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"2022020901350736000_12.2.303.142","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa2033130","article-title":"A neutralizing monoclonal antibody for hospitalized patients with Covid-19","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"key":"2022020901350736000_12.2.303.143","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2022020901350736000_12.2.303.144","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet"},{"key":"2022020901350736000_12.2.303.145","first-page":"132","article-title":"Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome","volume":"93","author":"Puy\u00f3","year":"2020","journal-title":"An Pediatr"},{"key":"2022020901350736000_12.2.303.146","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.cllc.2020.08.002","article-title":"Tocilizumab for COVID-19 pneumonia in a patient with non-small-cell lung cancer treated with chemoimmunotherapy","volume":"22","author":"Bonomi","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"2022020901350736000_12.2.303.147","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/imt-2020-0067","article-title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors","volume":"12","author":"Bersanelli","year":"2020","journal-title":"Immunotherapy"},{"key":"2022020901350736000_12.2.303.148","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12889-020-10103-x","article-title":"Misinformation about COVID-19: evidence for differential latent profiles and a strong association with trust in science","volume":"21","author":"Agley","year":"2021","journal-title":"BMC Public Health"},{"key":"2022020901350736000_12.2.303.149","first-page":"CD013587","article-title":"Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19","volume":"2","author":"Singh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2022020901350736000_12.2.303.150","first-page":"CD015017","article-title":"Ivermectin for preventing and treating COVID-19","volume":"7","author":"Popp","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2022020901350736000_12.2.303.151","doi-asserted-by":"crossref","unstructured":"Kamel AM Monem MSA Sharaf NA Magdy N Farid SF . Efficacy and safety of azithromycin in Covid-19 patients: a systematic review and meta-analysis of randomized clinical trials. Rev Med Virol 2021 Jun 2 [Epub ahead of print].","DOI":"10.1002\/rmv.2258"},{"key":"2022020901350736000_12.2.303.152","doi-asserted-by":"crossref","first-page":"e7978","DOI":"10.5867\/medwave.2020.06.7978","article-title":"Vitamin C for COVID-19: a living systematic review","volume":"20","author":"Baladia","year":"2020","journal-title":"Medwave"},{"key":"2022020901350736000_12.2.303.153","doi-asserted-by":"crossref","first-page":"e210369","DOI":"10.1001\/jamanetworkopen.2021.0369","article-title":"Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID A to Z randomized clinical trial","volume":"4","author":"Thomas","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2022020901350736000_12.2.303.154","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-460121"},{"key":"2022020901350736000_12.2.303.155","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02374.x"},{"key":"2022020901350736000_12.2.303.156","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1111\/jth.15463","article-title":"The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19","volume":"19","author":"Li","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2022020901350736000_12.2.303.157","unstructured":"COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020."},{"key":"2022020901350736000_12.2.303.158","doi-asserted-by":"publisher","DOI":"10.1055\/a-1178-3551"},{"key":"2022020901350736000_12.2.303.159","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1055\/s-0040-1714275","article-title":"Thrombosis and hemostasis issues in cancer patients with COVID-19","volume":"46","author":"Horowitz","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"2022020901350736000_12.2.303.160","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1016\/S2352-3026(21)00105-8","article-title":"COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year","volume":"8","author":"Leentjens","year":"2021","journal-title":"Lancet Haematol"},{"key":"2022020901350736000_12.2.303.161","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915103"},{"key":"2022020901350736000_12.2.303.162","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/S0049-3848(16)30128-1","article-title":"OC-11\u2014anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism","volume":"140","author":"Young","year":"2016","journal-title":"Thromb Res"},{"key":"2022020901350736000_12.2.303.163","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-0038-1657516","article-title":"Efficacy and safety of oral anticoagulation in patients with cancer","volume":"78","author":"Bona","year":"1997","journal-title":"Thromb Haemost"},{"key":"2022020901350736000_12.2.303.164","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14929"},{"key":"2022020901350736000_12.2.303.165","doi-asserted-by":"crossref","first-page":"100761","DOI":"10.1016\/j.blre.2020.100761","article-title":"Coagulation and anticoagulation in COVID-19","volume":"47","author":"Hadid","year":"2021","journal-title":"Blood Rev"},{"key":"2022020901350736000_12.2.303.166","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2710"},{"key":"2022020901350736000_12.2.303.167","doi-asserted-by":"crossref","unstructured":"Loggers ET Wulff-Burchfield EM Subbiah IM Khaki AR Egan P Farmakiotis D Code status and outcomes in patients with cancer and COVID-19: a COVID-19 and Cancer Consortium (CCC19) registry analysis. J Clin Oncol 39, 2021 (suppl 15; abstr 12035).","DOI":"10.1200\/JCO.2021.39.15_suppl.12035"},{"key":"2022020901350736000_12.2.303.168","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/CRST.CRST_130_20","article-title":"Palliative care for advanced cancer patients in the COVID-19 pandemic: challenges and adaptations","volume":"3","author":"Singhai","year":"2020","journal-title":"Cancer Res Stat Treat"},{"key":"2022020901350736000_12.2.303.169","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00520-020-05809-y","article-title":"Palliative care for cancer patients with severe COVID-19: the challenge of uncertainty","volume":"29","author":"Cheng","year":"2021","journal-title":"Support Care Cancer"},{"key":"2022020901350736000_12.2.303.170","doi-asserted-by":"crossref","first-page":"17588359211042224","DOI":"10.1177\/17588359211042224","article-title":"Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective","volume":"13","author":"Soosaipillai","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"2022020901350736000_12.2.303.171","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0079"},{"key":"2022020901350736000_12.2.303.172","doi-asserted-by":"publisher","DOI":"10.1126\/science.abi8397"},{"key":"2022020901350736000_12.2.303.173","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1377\/hlthaff.2021.00619","article-title":"Vaccinations against COVID-19 may have averted up to 140,000 deaths in the United States","volume":"40","author":"Gupta","year":"2021","journal-title":"Health Aff"},{"key":"2022020901350736000_12.2.303.174","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/infdis\/jiab233","article-title":"Lives and costs saved by expanding and expediting coronavirus disease 2019 vaccination","volume":"224","author":"Bartsch","year":"2021","journal-title":"J Infect Dis"},{"key":"2022020901350736000_12.2.303.175","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2022020901350736000_12.2.303.176","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2022020901350736000_12.2.303.177","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544"},{"key":"2022020901350736000_12.2.303.178","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2020.12.019","article-title":"Commentary: SARS-CoV-2 vaccines and cancer patients","volume":"32","author":"Corti","year":"2021","journal-title":"Ann Oncol"},{"key":"2022020901350736000_12.2.303.179","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1817"},{"key":"2022020901350736000_12.2.303.180","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm695152e2"},{"key":"2022020901350736000_12.2.303.181","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41571-021-00487-z","article-title":"COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials","volume":"18","author":"Desai","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2022020901350736000_12.2.303.182","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00213-8"},{"key":"2022020901350736000_12.2.303.183","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00155-8"},{"key":"2022020901350736000_12.2.303.184","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1072"},{"key":"2022020901350736000_12.2.303.185","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2021.2675","article-title":"Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer","volume":"7","author":"Goshen-Lago","year":"2021","journal-title":"JAMA Oncol"},{"key":"2022020901350736000_12.2.303.186","doi-asserted-by":"crossref","unstructured":"Ligumsky H Safadi E Etan T Vaknin N Waller M Croll A Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients. J Natl Cancer Inst 2021 Aug 28 [Epub ahead of print].","DOI":"10.1093\/jnci\/djab174"},{"key":"2022020901350736000_12.2.303.187","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"2022020901350736000_12.2.303.188","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"key":"2022020901350736000_12.2.303.189","doi-asserted-by":"crossref","unstructured":"Benjamini O Rokach L Itchaki G Braester A Shvidel L Goldschmidt N Safety and efficacy of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia. Haematologica 2021 Jul 29 [Epub ahead of print].","DOI":"10.3324\/haematol.2021.279196"},{"key":"2022020901350736000_12.2.303.190","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am J Hematol"},{"key":"2022020901350736000_12.2.303.191","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.3390\/cancers13143573","article-title":"COVID-19 vaccine safety in cancer patients: a single centre experience","volume":"13","author":"So","year":"2021","journal-title":"Cancers"},{"key":"2022020901350736000_12.2.303.192","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01542-z"},{"key":"2022020901350736000_12.2.303.193","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29295"},{"key":"2022020901350736000_12.2.303.194","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","article-title":"mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial","volume":"22","author":"Oosting","year":"2021","journal-title":"Lancet Oncol"},{"key":"2022020901350736000_12.2.303.195","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0008"},{"key":"2022020901350736000_12.2.303.196","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"2022020901350736000_12.2.303.197","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"2022020901350736000_12.2.303.198","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"key":"2022020901350736000_12.2.303.199","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"key":"2022020901350736000_12.2.303.200","doi-asserted-by":"crossref","unstructured":"Mair MJ Berger JM Berghoff AS Starzer AM Ortmayr G Puhr HC Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations. JAMA Oncol 2021 Sep 30 [Epub ahead of print].","DOI":"10.1001\/jamaoncol.2021.5437"},{"key":"2022020901350736000_12.2.303.201","doi-asserted-by":"crossref","unstructured":"Wu JT La J Branch-Elliman W Huhmann LB Han S Parmigiani G Effectiveness of COVID-19 vaccination in cancer patients: a nationwide Veterans Affairs study. Ann Oncol 2021;32 (Suppl 5):S1129\u201363. Abstract nr 1562MO.","DOI":"10.1016\/j.annonc.2021.08.1555"},{"key":"2022020901350736000_12.2.303.202","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.09.001"},{"key":"2022020901350736000_12.2.303.203","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.06.002"},{"key":"2022020901350736000_12.2.303.204","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0139"},{"key":"2022020901350736000_12.2.303.205","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01090-6"},{"key":"2022020901350736000_12.2.303.206","doi-asserted-by":"crossref","first-page":"E410","DOI":"10.1002\/ajh.26322","article-title":"Serologic response to mRNA COVID-19 vaccination in lymphoma patients","volume":"96","author":"Jurgens","year":"2021","journal-title":"Am J Hematol"},{"key":"2022020901350736000_12.2.303.207","doi-asserted-by":"crossref","first-page":"E408","DOI":"10.1002\/ajh.26305","article-title":"Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib","volume":"96","author":"Guglielmelli","year":"2021","journal-title":"Am J Hematol"},{"key":"2022020901350736000_12.2.303.208","doi-asserted-by":"crossref","unstructured":"Mittelman M Magen O Barda N Dagan N Oster HS Leader A Effectiveness of the BNT162b2mRNA Covid-19 vaccine in patients with hematological neoplasms. Blood 2021 Oct 18 [Epub ahead of print].","DOI":"10.1182\/blood.2021013768"},{"key":"2022020901350736000_12.2.303.209","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.09.015"},{"key":"2022020901350736000_12.2.303.210","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-3554"},{"key":"2022020901350736000_12.2.303.211","doi-asserted-by":"crossref","unstructured":"Shapiro LC Thakkar A Campbell ST Forest SK Pradhan K Gonzalez-Lugo JD Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell 2021 Nov 16 [Epub ahead of print].","DOI":"10.1016\/j.ccell.2021.11.006"},{"key":"2022020901350736000_12.2.303.212","doi-asserted-by":"crossref","unstructured":"Parvathaneni K Torres-Rodriguez K Meng W Hwang W-T Frey N Naji A SARS-CoV-2 spike-specific T-cell responses in patients with B-cell depletion who received chimeric antigen receptor T-cell treatments. JAMA Oncol 2021 Nov 18 [Epub ahead of print].","DOI":"10.1001\/jamaoncol.2021.6030"},{"key":"2022020901350736000_12.2.303.213","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/jama.2021.15125","article-title":"Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273","volume":"326","author":"Steensels","year":"2021","journal-title":"JAMA"},{"key":"2022020901350736000_12.2.303.214","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8511"},{"key":"2022020901350736000_12.2.303.215","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.06.002"},{"key":"2022020901350736000_12.2.303.216","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.06.009"},{"key":"2022020901350736000_12.2.303.217","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109072"},{"key":"2022020901350736000_12.2.303.218","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8"},{"key":"2022020901350736000_12.2.303.219","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.063"},{"key":"2022020901350736000_12.2.303.220","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244126"},{"key":"2022020901350736000_12.2.303.221","doi-asserted-by":"crossref","unstructured":"Gilbert PB Montefiori DC McDermott AB Fong Y Benkeser D Deng W Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2021 Aug 15 [Epub ahead of print].","DOI":"10.1126\/science.abm3425"},{"key":"2022020901350736000_12.2.303.222","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/pai.13263","article-title":"Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover","volume":"31","author":"Soresina","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"2022020901350736000_12.2.303.223","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458520943791","article-title":"Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient","volume":"26","author":"Wurm","year":"2020","journal-title":"Mult Scler"},{"key":"2022020901350736000_12.2.303.224","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2550-z"},{"key":"2022020901350736000_12.2.303.225","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.023"},{"key":"2022020901350736000_12.2.303.226","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd3871"},{"key":"2022020901350736000_12.2.303.227","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-020-01143-2"},{"key":"2022020901350736000_12.2.303.228"},{"key":"2022020901350736000_12.2.303.229","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd2071"},{"key":"2022020901350736000_12.2.303.230","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00534-z"},{"key":"2022020901350736000_12.2.303.231","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ccell.2021.07.001","article-title":"Immune responses to COVID-19 vaccines in patients with cancer: promising results and a note of caution","volume":"39","author":"Griffiths","year":"2021","journal-title":"Cancer Cell"},{"key":"2022020901350736000_12.2.303.232","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s43018-021-00191-y","article-title":"Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy","volume":"2","author":"Thakkar","year":"2021","journal-title":"Nat Cancer"},{"key":"2022020901350736000_12.2.303.233","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejca.2020.06.017","article-title":"Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?","volume":"136","author":"Houot","year":"2020","journal-title":"Eur J Cancer"},{"key":"2022020901350736000_12.2.303.234","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00528-x"},{"key":"2022020901350736000_12.2.303.235","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2021.2155","article-title":"Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer","volume":"7","author":"Massarweh","year":"2021","journal-title":"JAMA Oncol"},{"key":"2022020901350736000_12.2.303.236","doi-asserted-by":"crossref","unstructured":"Tenforde MW Patel MM Ginde AA Douin DJ Talbot HK Casey JD Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States. medRxiv 2021.07.08.21259776 [Preprint]. 2021. Available from: https:\/\/doi.org\/10.1101\/2021.07.08.21259776.","DOI":"10.1101\/2021.07.08.21259776"},{"key":"2022020901350736000_12.2.303.237","doi-asserted-by":"crossref","unstructured":"Tenforde MW Patel MM Ginde AA Douin DJ Talbot HK Casey JD Effectiveness of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines for preventing coronavirus disease 2019 hospitalizations in the United States. Clin Infect Dis 2021 Aug 6 [Epub ahead of print].","DOI":"10.1093\/cid\/ciab687"},{"key":"2022020901350736000_12.2.303.238","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cmi.2021.06.036","article-title":"BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel","volume":"27","author":"Brosh-Nissimov","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2022020901350736000_12.2.303.239","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ccell.2021.10.003","article-title":"Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer","volume":"39","author":"McKenzie","year":"2021","journal-title":"Cancer Cell"},{"key":"2022020901350736000_12.2.303.240","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00558-2"},{"key":"2022020901350736000_12.2.303.241","doi-asserted-by":"crossref","unstructured":"Pagano L Salmanton-Garc\u00eda J Marchesi F Lopez-Garcia A Lamure S Itri F COVID-19 in vaccinated adult patients with hematological malignancies. Preliminary results from EPICOVIDEHA. Blood 2021 Nov 8 [Epub ahead of print].","DOI":"10.1182\/blood.2021014124"},{"key":"2022020901350736000_12.2.303.242","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2111462"},{"key":"2022020901350736000_12.2.303.243","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ccell.2021.06.015","article-title":"Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient","volume":"39","author":"Hill","year":"2021","journal-title":"Cancer Cell"},{"key":"2022020901350736000_12.2.303.244","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2114255\/SUPPL_FILE\/NEJMOA2114255_DISCLOSURES.PDF"},{"key":"2022020901350736000_12.2.303.245","doi-asserted-by":"crossref","unstructured":"Atmar RL Lyke KE Deming ME Jackson LA Branche AR El Sahly HM Heterologous SARS-CoV-2 booster vaccinations: preliminary report. medRxiv 2021.10.10.21264827 [Preprint]. 2021. Available from: https:\/\/doi.org\/10.1101\/2021.10.10.21264827.","DOI":"10.1101\/2021.10.10.21264827"},{"key":"2022020901350736000_12.2.303.246","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0874-8"},{"key":"2022020901350736000_12.2.303.247","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1133"},{"key":"2022020901350736000_12.2.303.248","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.annonc.2020.07.010","article-title":"Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"2022020901350736000_12.2.303.249","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1200\/GO.20.00423","article-title":"Delivering cancer care during the COVID-19 pandemic: recommendations and lessons learned from ASCO global webinars","volume":"6","author":"Jazieh","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"2022020901350736000_12.2.303.250","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.radonc.2020.04.001","article-title":"Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: an ESTRO-ASTRO consensus statement","volume":"146","author":"Guckenberger","year":"2020","journal-title":"Radiother Oncol"},{"key":"2022020901350736000_12.2.303.251","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08461-2"},{"key":"2022020901350736000_12.2.303.252","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.eururo.2020.08.030","article-title":"The impact of the COVID-19 pandemic on genitourinary cancer care: re-envisioning the future","volume":"78","author":"Wallis","year":"2020","journal-title":"Eur Urol"},{"key":"2022020901350736000_12.2.303.253","doi-asserted-by":"publisher","DOI":"10.1200\/go.20.00639"},{"key":"2022020901350736000_12.2.303.254","doi-asserted-by":"crossref","first-page":"e13290","DOI":"10.1111\/ecc.13290","article-title":"Cancer has not gone away: a primary care perspective to support a balanced approach for timely cancer diagnosis during COVID-19","volume":"29","author":"Helsper","year":"2020","journal-title":"Eur J Cancer Care"},{"key":"2022020901350736000_12.2.303.255","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.17267"},{"key":"2022020901350736000_12.2.303.256","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/CCI.20.00068","article-title":"Effects of the COVID-19 pandemic on cancer-related patient encounters","volume":"4","author":"London","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"2022020901350736000_12.2.303.257","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.20.00134"},{"key":"2022020901350736000_12.2.303.258","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7004a1","article-title":"Impact of COVID-19 on cervical cancer screening rates among women aged 21\u201365 years in a large integrated health care system\u2014Southern California, January 1\u2013September 30, 2019, and January 1\u2013September 30, 2020","volume":"70","author":"Miller","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022020901350736000_12.2.303.259","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1470-2045(20)30265-5","article-title":"Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands","volume":"21","author":"Dinmohamed","year":"2020","journal-title":"Lancet Oncol"},{"key":"2022020901350736000_12.2.303.260","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd3377"},{"key":"2022020901350736000_12.2.303.261","doi-asserted-by":"crossref","unstructured":"Ward ZJ Walbaum M Walbaum B Guzman MJ de la Jara JJ Nervi B Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis. Lancet Oncol 2021 ;22:1427\u201337.","DOI":"10.1016\/S1470-2045(21)00426-5"},{"key":"2022020901350736000_12.2.303.262","doi-asserted-by":"crossref","first-page":"106586","DOI":"10.1016\/j.ypmed.2021.106586","article-title":"Measuring the impact of the COVID-19 pandemic on organized cancer screening and diagnostic follow-up care in Ontario, Canada: a provincial, population-based study","volume":"151","author":"Walker","year":"2021","journal-title":"Prev Med"},{"key":"2022020901350736000_12.2.303.263","doi-asserted-by":"crossref","first-page":"106606","DOI":"10.1016\/j.ypmed.2021.106606","article-title":"COVID-19 and cancer screening in Scotland: a national and coordinated approach to minimising harm","volume":"151","author":"Campbell","year":"2021","journal-title":"Prev Med"},{"key":"2022020901350736000_12.2.303.264","doi-asserted-by":"crossref","first-page":"106559","DOI":"10.1016\/j.ypmed.2021.106559","article-title":"COVID-19 impact on screening test volume through the National Breast and Cervical Cancer Early Detection Program, January-June 2020, in the United States","volume":"151","author":"DeGroff","year":"2021","journal-title":"Prev Med"},{"key":"2022020901350736000_12.2.303.265","doi-asserted-by":"crossref","first-page":"106640","DOI":"10.1016\/j.ypmed.2021.106640","article-title":"The trajectory of racial\/ethnic disparities in the use of cancer screening before and during the COVID-19 pandemic: a large U.S. academic center analysis","volume":"151","author":"Marcondes","year":"2021","journal-title":"Prev Med"},{"key":"2022020901350736000_12.2.303.266","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2747"},{"key":"2022020901350736000_12.2.303.267","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/hed.26165","article-title":"Care of immunocompromised patients with head and neck cancer during the COVID-19 pandemic: two challenging and informative clinical cases","volume":"42","author":"Civantos","year":"2020","journal-title":"Head Neck"},{"key":"2022020901350736000_12.2.303.268","doi-asserted-by":"crossref","first-page":"100241","DOI":"10.1016\/j.jcpo.2020.100241","article-title":"Minimizing transmission of COVID-19 while delivering optimal cancer care in a National Cancer Centre","volume":"25","author":"Chiang","year":"2020","journal-title":"J Cancer Policy"},{"key":"2022020901350736000_12.2.303.269","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijrobp.2020.06.054","article-title":"Radiation fractionation schedules published during the COVID-19 pandemic: a systematic review of the quality of evidence and recommendations for future development","volume":"108","author":"Thomson","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022020901350736000_12.2.303.270","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1001\/jamaoncol.2020.4408","article-title":"Changes in lung cancer treatment as a result of the coronavirus disease 2019 pandemic","volume":"6","author":"Elkrief","year":"2020","journal-title":"JAMA Oncol"},{"key":"2022020901350736000_12.2.303.271","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1200\/JCO.20.01474","article-title":"COVID-19 and cancer care: ensuring safety while transforming care delivery","volume":"38","author":"Mulvey","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022020901350736000_12.2.303.272","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2020.04.003","article-title":"Lessons from the coronavirus disease 2019 pandemic: will virtual patient management reshape uro-oncology in Germany?","volume":"132","author":"Rodler","year":"2020","journal-title":"Eur J Cancer"},{"key":"2022020901350736000_12.2.303.273","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.009"},{"key":"2022020901350736000_12.2.303.274","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4087"},{"key":"2022020901350736000_12.2.303.275","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043828"},{"key":"2022020901350736000_12.2.303.276","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/OP.20.00520","article-title":"Telehealth for cancer care in veterans: opportunities and challenges revealed by COVID","volume":"17","author":"Jiang","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"2022020901350736000_12.2.303.277","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/pon.5468","article-title":"Bridging the distance: continuing psycho-oncological care via video-consults during the COVID-19 pandemic","volume":"29","author":"van der Lee","year":"2020","journal-title":"Psychooncology"},{"key":"2022020901350736000_12.2.303.278","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7943"},{"key":"2022020901350736000_12.2.303.279","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocaa067"},{"key":"2022020901350736000_12.2.303.280","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.9897"},{"key":"2022020901350736000_12.2.303.281","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/hed.26195","article-title":"Transition to a virtual multidisciplinary tumor board during the COVID-19 pandemic: University of Pittsburgh experience","volume":"42","author":"Dharmarajan","year":"2020","journal-title":"Head Neck"},{"key":"2022020901350736000_12.2.303.282","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1200\/JCO.2020.39.28_suppl.152","article-title":"Fear of COVID-19: effects on mental health in under-resourced patients with cancer","volume":"39","author":"Lawhon","year":"2021","journal-title":"J Clin Oncol"},{"key":"2022020901350736000_12.2.303.283","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/jamia\/ocab132","article-title":"Increasing trust in real-world evidence through evaluation of observational data quality","volume":"8","author":"Blacketer","year":"2021","journal-title":"J Am Med Inform Assoc"},{"key":"2022020901350736000_12.2.303.284","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pds.4924","article-title":"Data linkage in pharmacoepidemiology: a call for rigorous evaluation and reporting","volume":"29","author":"Pratt","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022020901350736000_12.2.303.285","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19478-2"},{"key":"2022020901350736000_12.2.303.286","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7"},{"key":"2022020901350736000_12.2.303.287","doi-asserted-by":"crossref","unstructured":"Pearl J . An introduction to causal inference. Int J Biostat 2010;6: Article 7.","DOI":"10.2202\/1557-4679.1203"},{"key":"2022020901350736000_12.2.303.288","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110362"},{"key":"2022020901350736000_12.2.303.289","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jamaoncol.2020.6639","article-title":"Scientific rigor in the age of COVID-19","volume":"7","author":"Shyr","year":"2021","journal-title":"JAMA Oncol"},{"key":"2022020901350736000_12.2.303.290","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jamaoncol.2021.4083","article-title":"COVID-19 and cancer: a review of the registry-based pandemic response","volume":"7","author":"Desai","year":"2021","journal-title":"JAMA Oncol"},{"key":"2022020901350736000_12.2.303.291","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/eahr.500025","article-title":"Ethical tensions resulting from interpreter involvement in the consent process","volume":"41","author":"Barwise","year":"2019","journal-title":"Ethics Hum Res"},{"key":"2022020901350736000_12.2.303.292","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-007-0136-1"},{"key":"2022020901350736000_12.2.303.293","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/jamia\/ocaa078","article-title":"Impact of the digital divide in the age of COVID-19","volume":"27","author":"Ramsetty","year":"2020","journal-title":"J Am Med Inform Assoc"},{"key":"2022020901350736000_12.2.303.294","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/CCI.20.00054","article-title":"Crowdsourcing in crisis: rising to the occasion","volume":"4","author":"Desai","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"2022020901350736000_12.2.303.295","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s43018-020-0065-z","article-title":"Crowdsourcing a crisis response for COVID-19 in oncology","volume":"1","author":"Desai","year":"2020","journal-title":"Nat Cancer"},{"key":"2022020901350736000_12.2.303.296","doi-asserted-by":"crossref","unstructured":"Agha M Blake M Chilleo C Wells A Haidar G . Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv 2021.04.06.21254949 [Preprint]. 2021. Available from: https:\/\/doi.org\/10.1101\/2021.04.06.21254949.","DOI":"10.1101\/2021.04.06.21254949"},{"key":"2022020901350736000_12.2.303.297","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjh.17568","article-title":"Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia","volume":"194","author":"Harrington","year":"2021","journal-title":"Br J Haematol"},{"key":"2022020901350736000_12.2.303.298","unstructured":"Fendler A Au L Shepherd STC Byrne F Cerrone M Boos LA Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nat Cancer 2021 ;2:1321\u201337."},{"key":"2022020901350736000_12.2.303.299","doi-asserted-by":"crossref","unstructured":"Rottenberg Y Grinshpun A Ben-Dov IZ Djian EO Wolf DG Kadouri L . Assessment of response to a third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment. JAMA Oncol 2021 Nov 23 [Epub ahead of print].","DOI":"10.1001\/jamaoncol.2021.6764"},{"key":"2022020901350736000_12.2.303.300","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-021-00530-3","article-title":"The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1158\/2159-8290.CD-21-1368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T09:37:46Z","timestamp":1644399466000},"score":1,"resource":{"primary":{"URL":"http:\/\/cancerdiscovery.aacrjournals.org\/lookup\/doi\/10.1158\/2159-8290.CD-21-1368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":300,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,9]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1158\/2159-8290.CD-21-1368"],"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-21-1368","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,10]]}}}